Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M. Source: BioSpace You Might Also Like Diffusion Pharma Names Chief Business Officer August 22, 2017 Zealand Pharma Increases Its Share Capital As A Consequence Of Exercise Of Employee Warrants May 29, 2017 GTX Corp To Host Key Opinion Leader Luncheon On The Topic Of Stress Urinary Incontinence On September 28th In New York City September 21, 2017
Zealand Pharma Increases Its Share Capital As A Consequence Of Exercise Of Employee Warrants May 29, 2017
GTX Corp To Host Key Opinion Leader Luncheon On The Topic Of Stress Urinary Incontinence On September 28th In New York City September 21, 2017
